Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2012, Article ID 437569, 8 pages
http://dx.doi.org/10.1155/2012/437569
Review Article

New Insight into the Treatment of Advanced Differentiated Thyroid Cancer

1Department of Surgery, University of Arizona, Tucson, AZ 85724-5131, USA
2The University of Arizona Cancer Center, Tucson, AZ 85719-1454, USA

Received 3 November 2012; Accepted 12 December 2012

Academic Editor: Maria Grazia Chiofalo

Copyright © 2012 Arash Safavi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. I. Sherman, “Thyroid carcinoma,” The Lancet, vol. 361, no. 9356, pp. 501–511, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Agate, L. Lorusso, and R. Elisei, “New and old knowledge on differentiated thyroid cancer epidemiology and risk factors,” Journal of Endocrinological Investigation, vol. 35, no. 6, pp. 3–9, 2012. View at Google Scholar
  3. American Cancer Society, Cancer Facts and Figures 2012, American Cancer Society, Atlanta, Ga, USA, 2012.
  4. A. Antonelli, P. Fallahi, S. M. Ferrari et al., “Dedifferentiated thyroid cancer: a therapeutic challenge,” Biomedicine and Pharmacotherapy, vol. 62, no. 8, pp. 559–563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. Tuttle, “Novel therapeutic options for aggressive thyroid cancer: integrating information from the recent clinical trials into clinical practice,” Clinical Thryoidology, vol. 21, pp. 3–7, 2009. View at Google Scholar
  6. M. Xing, “Recent advances in molecular biology of thyroid cancer and their clinical implications,” Otolaryngologic Clinics of North America, vol. 41, no. 6, pp. 1135–1146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. S. I. Sherman, L. J. Wirth, J. P. Droz et al., “Motesanib diphosphate in progressive differentiated thyroid cancer,” New England Journal of Medicine, vol. 359, no. 1, pp. 31–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. E. E. W. Cohen, L. S. Rosen, E. E. Vokes et al., “Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4708–4713, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Gupta-Abramson, A. B. Troxel, A. Nellore et al., “Phase II trial of sorafenib in advanced thyroid cancer,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4714–4719, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. T. Kloos, M. D. Ringel, M. V. Knopp et al., “Phase II trial of sorafenib in metastatic thyroid cancer,” Journal of Clinical Oncology, vol. 27, pp. 1675–1684, 2009. View at Publisher · View at Google Scholar
  11. H. Hoftijzer, K. A. Heemstra, H. Morreau et al., “Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma,” European Journal of Endocrinology, vol. 161, no. 6, pp. 923–931, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ahmed, Y. Barbachano, A. Riddell et al., “Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population,” European Journal of Endocrinology, vol. 165, no. 2, pp. 315–322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Marotta, V. Ramundo, L. Camera et al., “Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET,” Clinical Endocrinology. In press. View at Publisher · View at Google Scholar
  14. L. L. Carr, D. A. Mankoff, B. H. Goulart et al., “Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation,” Clinical Cancer Research, vol. 16, no. 21, pp. 5260–5268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. E. E. Cohen, B. M. Needles, K. J. Cullen et al., “Phase 2 study of sunitinib in refractory thyroid cancer,” Journal of Clinical Oncology, vol. 26, no. 20, article 6025, 2008. View at Google Scholar
  16. K. C. Bible, V. J. Suman, J. R. Molina et al., “Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study,” The Lancet Oncology, vol. 11, no. 10, pp. 962–972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Mrozek, R. T. Kloos, M. D. Ringel et al., “Phase II study of celecoxib in metastatic differentiated thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2201–2204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Woyach, R. T. Kloos, M. D. Ringel et al., “Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 164–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. B. Ain, C. Lee, and K. D. Williams, “Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas,” Thyroid, vol. 17, no. 7, pp. 663–670, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. K. B. Ain, C. Lee, K. Holbrook, J. Dziba, and K. Williams, “Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results,” Journal of Clinical Oncology, 6027, 2008. View at Google Scholar
  21. E. Kebebew, S. Lindsay, O. H. Clark, K. A. Woeber, R. Hawkins, and F. S. Greenspan, “Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer,” Thyroid, vol. 19, no. 9, pp. 953–956, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Y. Liu, M. P. Stokkel, H. A. Morreau, A. M. Pereira, J. A. Romijn, and J. W. A. Smit, “Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma,” Clinical Endocrinology, vol. 68, no. 4, pp. 605–609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Ho, R. K. Grewal, R. Leboeuf et al., “Reacquisition of RAI uptake in RAI-refractory, metastatic thyroid cancers by pretreatment with the selective MEK inhibitor, selumetinib,” Journal of Clinical Oncology, vol. 30, article 5509, 2012. View at Google Scholar
  24. V. Trovisco, P. Soares, and M. Sobrinho-Simões, “B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas,” Human Pathology, vol. 37, no. 7, pp. 781–786, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Ciampi and Y. E. Nikiforov, “Alterations of the BRAF gene in thyroid tumors,” Endocrine Pathology, vol. 16, no. 3, pp. 163–172, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Xing, “BRAF mutation in thyroid cancer,” Endocrine-Related Cancer, vol. 12, no. 2, pp. 245–262, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Gimm, “Thyroid cancer,” Cancer Letters, vol. 163, no. 2, pp. 143–156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Rosai, “Handling of thyroid follicular patterned lesions,” Endocrine Pathology, vol. 16, no. 4, pp. 279–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. R. M. Quiros, H. G. Ding, P. Gattuso, R. A. Prinz, and X. Xu, “Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations,” Cancer, vol. 103, no. 11, pp. 2261–2268, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Tallini and S. L. Asa, “RET oncogene activation in papillary thyroid carcinoma,” Advances in Anatomic Pathology, vol. 8, no. 6, pp. 345–354, 2001. View at Google Scholar · View at Scopus
  31. E. T. Kimura, M. N. Nikiforova, Z. Zhu, J. A. Knauf, Y. E. Nikiforov, and J. A. Fagin, “High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma,” Cancer Research, vol. 63, no. 7, pp. 1454–1457, 2003. View at Google Scholar · View at Scopus
  32. V. Marotta, A. Guerra, M. R. Sapio, and M. Vitale, “RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint,” European Journal of Endocrinology, vol. 165, no. 4, pp. 499–507, 2011. View at Publisher · View at Google Scholar
  33. V. Marotta, M. R. Sapio, A. Guerra, and M. Vitale, “BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma,” Expert Opinion on Medical Diagnostics, vol. 5, no. 4, pp. 277–290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. H. M. Rabes, E. P. Demidchik, J. D. Sidorow et al., “Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications,” Clinical Cancer Research, vol. 6, no. 3, pp. 1093–1103, 2000. View at Google Scholar · View at Scopus
  35. M. N. Nikiforova, R. A. Lynch, P. W. Biddinger et al., “RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 2318–2326, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. A. R. Marques, C. Espadinha, A. L. Catarino et al., “Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 8, pp. 3947–3952, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Gimm, A. Perren, L. P. Weng et al., “Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors,” American Journal of Pathology, vol. 156, no. 5, pp. 1693–1700, 2000. View at Google Scholar · View at Scopus
  38. M. D. Ringel, N. Hayre, J. Saito et al., “Overexpression and overactivation of Akt in thyroid carcinoma,” Cancer Research, vol. 61, no. 16, pp. 6105–6111, 2001. View at Google Scholar · View at Scopus
  39. P. Bruni, A. Boccia, G. Baldassarre et al., “PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27(kip1),” Oncogene, vol. 19, no. 28, pp. 3146–3155, 2000. View at Google Scholar · View at Scopus
  40. Z. Liu, P. Hou, M. Ji et al., “Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 3106–3116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. V. Vasko, M. Ferrand, J. Di Cristofaro, P. Carayon, J. F. Henry, and C. de Micco, “Specific pattern of RAS oncogene mutations in follicular thyroid tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2745–2752, 2003. View at Google Scholar · View at Scopus
  42. M. Fassnacht, M. C. Kreissl, D. Weismann, and B. Allolio, “New targets and therapeutic approaches for endocrine malignancies,” Pharmacology and Therapeutics, vol. 123, no. 1, pp. 117–141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. I. Sherman, “Targeted therapy of thyroid cancer,” Biochemical Pharmacology, vol. 80, no. 5, pp. 592–601, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Klein, J. M. Vignaud, V. Hennequin et al., “Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 656–658, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Y. Soh, M. S. Eigelberger, K. J. Kim et al., “Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo,” Surgery, vol. 128, no. 6, pp. 1059–1066, 2000. View at Google Scholar · View at Scopus
  46. J. Capdevila, L. Iglesias, I. Halperin et al., “Sorafenib in metastatic thyroid cancer,” Endocrine-Related Cancers, vol. 19, no. 2, pp. 209–216, 2012. View at Publisher · View at Google Scholar
  47. S. I. Sherman, B. Jarzab, M. E. Cabanillas et al., “A phase II trial of the multi-targeted kinase inhibitor, Lenvatinib (E7080), in advanced radioiodine-refractory differentiated thyroid cancer (DTC),” Journal of Clinical Oncology, vol. 29, no. 15, article 5503, 2011. View at Google Scholar
  48. S. Leboulleux, L. Bastholt, T. Krause et al., “Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial,” The Lancet Oncology, vol. 13, no. 9, pp. 897–905, 2012. View at Publisher · View at Google Scholar
  49. D. S. Hong, M. E. Cabanillas, J. Wheler et al., “Inhibition of the ras/raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 4, pp. 997–1005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. M. E. Cabanillas, M. S. Brose, D. A. Ramies et al., “Anti-tumor activity observed in a cohort of patients with differentiated thyroid cancer in a phase 1 study of cabozantinib (XL184),” Journal of Clinical Oncology, p. 5547, 2012. View at Google Scholar
  51. Y. Y. Liu, M. P. Stokkel, A. M. Pereira et al., “Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma,” European Journal of Endocrinology, vol. 154, no. 4, pp. 525–531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines),” Journal of the National Cancer Institute, vol. 92, pp. 205–216, 2000. View at Publisher · View at Google Scholar
  54. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Mizuki Nishino, J. P. Jagannathan, and K. M. Krajewski, “Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST,” American Journal of Roentgenology, vol. 198, no. 4, pp. 737–745, 2012. View at Publisher · View at Google Scholar